Despite rising interest rates and the uncertainty of midterm elections, Asad Haider of Goldman Sachs sees promise in Big Pharma and biotech.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock ·
Barrons.com
·
Photograph by Ike Edeani
